ACE-031 Peptide: Research Guide, Mechanism, and What Science Says (2026)

What Is ACE-031?

ACE-031 — formally known as Myostatin Inhibitory Peptide 7 (CAS 1621169-52-5) — is not a traditional peptide in the short-chain amino acid sense. It is a recombinant fusion protein engineered from two functional components: the ligand-binding domain of the human activin receptor type IIB (ACVR2B) fused to the Fc region of human IgG1. This design gives the molecule a dual purpose — it acts as a decoy receptor, intercepting myostatin and a cluster of related signaling proteins before they can bind to and activate their native receptors on muscle and bone cells.

Myostatin (growth differentiation factor 8, or GDF-8) is a member of the TGF-β superfamily and is one of the most well-characterized negative regulators of skeletal muscle mass. Animals and humans with naturally occurring myostatin deficiencies exhibit dramatically increased muscle mass and reduced body fat — a phenomenon documented in Belgian Blue cattle, whippet dogs, and rare human cases. ACE-031 was developed by Acceleron Pharma to pharmacologically replicate this effect in patients with conditions such as Duchenne muscular dystrophy and other muscle-wasting disorders.

Because ACVR2B binds not only myostatin but also activin A, activin B, GDF-11, and BMP-9, ACE-031 has a broader scope of action than simple myostatin-only blockers. Researchers note that this broader ligand capture may explain both its potent anabolic effects and some of its off-target findings in clinical data.

How ACE-031 Works: Mechanism of Action

Understanding how ACE-031 operates requires a brief look at the ACVR2B signaling pathway. In healthy muscle tissue, myostatin binds to the ACVR2B receptor on the surface of muscle satellite cells. This binding initiates an intracellular SMAD2/3 signaling cascade that ultimately suppresses protein synthesis and promotes muscle atrophy. ACE-031 intervenes upstream of this process.

When administered, ACE-031 circulates in the bloodstream and functions as a ligand trap — its ACVR2B domain has a higher binding affinity for myostatin and related ligands than the native membrane-bound receptor does. By sequestering these ligands in circulation, ACE-031 prevents them from ever reaching muscle cells. The IgG1-Fc fusion region extends the molecule's half-life significantly (estimated at several days to weeks in human pharmacokinetic studies), making it suitable for infrequent dosing compared to conventional peptides.

The breadth of ligands captured by ACE-031 distinguishes it from more selective myostatin inhibitors like follistatin or anti-myostatin antibodies. Researchers hypothesize that blocking activin A, which also plays a role in bone remodeling and reproductive signaling, may contribute to both additional anabolic benefits and unintended physiological effects observed in early trials.

ACE-031 Research: Clinical Trials and Key Findings

ACE-031 progressed to human clinical trials, which is noteworthy for a research peptide-adjacent compound. A Phase 1 single ascending-dose study published in peer-reviewed literature evaluated its safety, tolerability, pharmacokinetics, and pharmacodynamic effects in healthy volunteers. Key findings from that study include:

• Tolerability: ACE-031 was generally well-tolerated at the doses studied. The most commonly reported adverse event was injection site erythema (localized redness), consistent with subcutaneous protein-based therapeutics.
• Pharmacokinetics: Mean ACE-031 AUC(0-∞) and Cmax increased in a roughly linear (dose-proportional) manner across the ascending dose cohorts, suggesting predictable pharmacokinetic behavior.
• Lean mass: Even in the single-dose format, measurable increases in lean body mass were detected at higher dose levels, supporting its mechanism of action.
• Bone biomarkers: Changes in bone formation and resorption markers were detected, suggesting ACE-031 influences bone metabolism — likely through inhibition of activin and GDF-11 signaling in addition to myostatin.

Acceleron Pharma also conducted Phase 2 trials in patients with Duchenne muscular dystrophy. These trials were ultimately paused due to adverse findings including nosebleeds (epistaxis), gum bleeding, and skin telangiectasias (dilated small blood vessels) in some participants. Researchers attributed these vascular effects to the compound's inhibition of activins and BMPs involved in vascular homeostasis. The program was not advanced to Phase 3.

In the research context, ACE-031 has also been studied for its effects on:

• Bone density: Preclinical rodent models showed increased bone mineral density and trabecular bone volume, suggesting potential relevance to osteoporosis research
• Metabolic parameters: Some animal studies noted reductions in fat mass alongside increases in lean tissue — an effect attributed to the multifactorial role of activin signaling in energy metabolism
• Muscle-wasting conditions: Research models of cachexia, muscular dystrophy, and sarcopenia have explored ACE-031's potential to preserve or restore muscle mass under catabolic conditions

ACE-031 vs. Other Myostatin Pathway Modulators

ACE-031 is not the only research compound targeting the myostatin pathway. Researchers and biohackers following this space often compare it against several related compounds:

Follistatin (FST-344): A naturally occurring glycoprotein that binds and neutralizes myostatin, activin, and related ligands. Follistatin is sometimes compared to ACE-031 due to its similar broad-spectrum ligand capture, but it is a naturally occurring protein rather than a rationally engineered fusion construct. Delivery methods differ significantly.

GDF-11 inhibition research: Given ACE-031 also neutralizes GDF-11, there is research overlap with studies exploring GDF-11's role in aging and tissue rejuvenation. This adds another dimension to ACE-031's research profile beyond pure muscle growth.

Peptide-based ACVR2B modulators: Shorter synthetic peptides derived from the ACVR2B binding domain have been explored, but none have matched ACE-031's potency or half-life in preclinical comparisons.

Compared to MK-677 (ibutamoren) or Ipamorelin, which work via the growth hormone axis to promote muscle growth indirectly, ACE-031 operates through an entirely separate pathway — making it mechanistically distinct and potentially complementary in research stacking contexts, though no human safety data exists for such combinations.

What to Look for When Sourcing ACE-031 for Research

ACE-031 presents unique sourcing challenges compared to conventional research peptides. Because it is a large recombinant fusion protein rather than a short synthetic peptide, its production requires mammalian or expression-system manufacturing — a significantly more complex and expensive process than standard solid-phase peptide synthesis. This complexity creates a substantial quality-control challenge in the research supply chain.

A 2025 study published in Drug Testing and Analysis specifically examined black-market ACE-031 samples using gel electrophoresis and LC-MS/MS tryptic digest analysis. The findings confirmed that some commercially available research-grade ACE-031 samples do contain the correct protein sequence, but others showed contamination, degradation, or misrepresented concentrations. This underscores the critical importance of rigorous vendor vetting for this compound in particular.

When evaluating vendors, researchers should be aware that ACE-031 is significantly more expensive to produce than conventional peptides like BPC-157 or TB-500. Pricing well below market rates is a strong red flag for substituted or underdosed product. Ascension Peptides is one vendor that researchers have cited for providing appropriate documentation on larger fusion proteins, though independent verification of any COA is always recommended.

Legal Status and Research Use of ACE-031

ACE-031 is not approved by the FDA or any major regulatory agency for human therapeutic use. Its clinical development was paused before Phase 3 trials, meaning it has never received marketing authorization. In most countries, including the United States, ACE-031 exists in a regulatory gray area as a research chemical — legal to purchase and possess for legitimate laboratory research purposes but not for human consumption or clinical administration.

Researchers and institutions working with ACE-031 should be aware of their local regulations regarding recombinant proteins and biologics. Unlike small-molecule research chemicals, large fusion proteins like ACE-031 may face different regulatory scrutiny depending on jurisdiction.

In competitive sports contexts, ACE-031 is banned by the World Anti-Doping Agency (WADA) under its category of hormone and metabolic modulators, and detection methods including the LC-MS/MS tryptic digest approach described in the 2025 Drug Testing and Analysis paper are actively being developed and validated.

Frequently Asked Questions About ACE-031

Summary: ACE-031 Research Outlook

ACE-031 represents one of the most scientifically substantive entries in the research compound space. Unlike many peptides discussed in biohacking communities without any human clinical data, ACE-031 has been studied in Phase 1 and Phase 2 human trials — providing researchers with real pharmacokinetic data, dose-response relationships, and a documented adverse event profile. Its mechanism as a broad ACVR2B ligand trap gives it unique research value in muscle biology, bone metabolism, and metabolic research.

The pausing of clinical development due to vascular adverse events is an important data point that underscores the complexity of broadly inhibiting the activin/myostatin signaling network. Researchers approaching ACE-031 should do so with a thorough understanding of its full ligand capture profile, not just its myostatin-inhibiting headline property.

For those sourcing ACE-031 for legitimate research purposes, the analytical complexity of verifying this compound's authenticity is substantially higher than for conventional synthetic peptides — making rigorous COA review, independent analytical verification, and careful vendor selection essential steps rather than optional ones.